359090.Kq
The company operates in the healthcare diagnostics segment, providing products and services related to life sciences tools and services, primarily generating revenue through the sale of diagnostic equipment and related consumables.
Business. The company operates in the healthcare diagnostics segment, providing products and services related to life sciences tools and services, primarily generating revenue through the sale of diagnostic equipment and related consumables.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, providing products and services related to life sciences tools and services, primarily generating revenue through the sale of diagnostic equipment and related consumables.
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 8,848,468,100, which represents 10.45% of total assets. The liquidity FPT (free cash flow to total liabilities) is not explicitly provided, but the current ratio of 1.19 suggests the company has sufficient short-term assets to cover its short-term liabilities. The debt-to-equity ratio of 0.15 indicates a conservative capital structure, with total liabilities accounting for only 40.45% of total equity.
Profitability metrics show a return on equity (ROE) of 5.23% and a return on assets (ROA) of 3.05%, both of which are below the industry median for Biotechnology & Medical Research. The company's net income of KRW 2,585,530,330 represents a 4.0% margin on revenue, which is in line with the industry average. However, the operating margin of 2.13% is slightly below the median, indicating potential inefficiencies in cost management.
The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic breakdown provided. This lack of diversification may expose the company to higher operational and market risks if demand in its primary market fluctuates. The absence of segment-specific revenue data limits the ability to assess geographic or product diversification.
The company's growth trajectory is modest, with no specific revenue growth rates provided in the financial data. The free cash flow of KRW 1,291,339,770 and capital expenditure of KRW -284,737,970 suggest a focus on maintaining operations rather than aggressive expansion. The outlook for the current fiscal year is neutral, with no significant changes expected in the near term.
Risk factors include a low liquidity risk and a low dilution risk, as no immediate filing-based liquidity or dilution flags were detected. The company's capital structure is conservative, with a low debt-to-equity ratio and a strong cash position. However, the negative operating cash flow of KRW -3,067,593,590 raises concerns about the sustainability of operations in the absence of external financing.
Recent events, as reflected in the financial data, include a stable share count with no dilution observed between basic and diluted shares outstanding. No specific recent filings or transcripts are provided in the data, so the narrative is limited to the financial snapshot and valuation metrics.
- The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.15 and a strong cash position.
- Profitability metrics, including ROE and ROA, are below the industry median, indicating potential inefficiencies in asset utilization and cost management.
- The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed, increasing exposure to market-specific risks.
- Free cash flow is positive, but the negative operating cash flow raises concerns about the sustainability of operations without external financing.
- The company is not currently facing immediate liquidity or dilution risks, but the negative operating cash flow may require monitoring in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 359090.KQ Market data — financials · 2026-05-26